Iris Pharma develops new CNV model

August 15, 2006

Nice, France-Iris Pharma, which specializes in the research and development of preclinical products in the field of ophthalmology, developed a new choroidial neovascularization (CNV) model in rats by using an argon laser.

Nice, France-Iris Pharma, which specializes in the research and development of preclinical products in the field of ophthalmology, developed a new choroidial neovascularization (CNV) model in rats by using an argon laser.

This model is in addition to many other validated animal models with ocular angiogenesis: retinopathy of prematurity hyperoxia in pup mice; retinal vascular permeation, induced by vascular endothelium growth factor in rabbits; and corneal neovascularization models induced by chemical burn (alcohol and sodium hydroxide) in rats, mice, and rabbits, or by corneal sutures in rabbits.

Related Content:

News